Close menu

November 17th, 2021 | 10:21 CET

TeamViewer, Aspermont, TUI - Three turnaround candidates in check

  • Investments
Photo credits:

If you still want to find favorable shares in today's market, you have to look for turnaround candidates. These companies are basically in a particular situation, which often leads to poor business figures. In some cases, business activities are questioned, and a restructuring concept is developed to guide the Company out of the crisis. If this succeeds, high profits beckon to investors. However, one should not reach for falling knives too early. Today, we analyze three companies where the turnaround could be imminent.

time to read: 4 minutes | Author: Armin Schulz

Table of contents:

    TeamViewer - Is Corona helping again?

    How did a winner of the Corona Crisis become a turnaround candidate? CEO Oliver Steil blames "homemade mistakes". At the beginning of the Corona pandemic, TeamViewer, the specialist for remote maintenance and video conferencing, had taken off. Due to the many home office jobs, remote maintenance and video conferencing were necessary, and the Company profited from this. TeamViewer wanted to secure the next future growth area, augmented reality, by acquiring Ubimax. The price seemed too high to experts, and the stock began to fall. But management wanted to raise its profile further and joined Manchester United as a shirt sponsor, which is rumored to cost around EUR 50 million per season.

    A profit warning followed at the beginning of October, and the share's slide accelerated once again. On November 3, the Company presented its figures for the third quarter. Sales increased by 9% YOY to EUR 127.7 million after adjusting for currency effects. EBITDA decreased by 27% to EUR 42.3 million, mainly due to the jersey sponsorship contract. The number of subscribers rose to 628,000, and the Company grew in the key account business in particular. The consolidated result was around EUR 3.7 million. If one compares the result with the previous year, when more than EUR 32 million was generated, investors' disappointment is understandable.

    However, the current ever-increasing incidences could increase sales again if the home office obligation is reintroduced. In addition, at its Capital Markets Day on November 10, the Company tried to convince investors that it had learned from its mistakes and presented a 10-point plan called Remax, which is to be implemented by the end of the third quarter of 2022 and bring optimizations in five areas. The plan failed to convince investors, and the share fell but did not mark a new low for the year, which lies at EUR 12.46. With a closing price above EUR 15.15, the share could form a first slight upward trend.

    Aspermont - A good year-end result

    If any industry is suffering from ongoing digitization and the Internet, it is the print media sector. Circulation has been declining almost everywhere for years. Aspermont owns the brand rights to magazines that can look back on a history of up to 185 years. Circulation dropped there, too, and so began the transformation into the leading media service provider for the global commodities industry. Readers can access online content with subscriptions. The Company has also significantly expanded its business areas in the B2B sector. Content marketing is offered for companies with on- and offline trade shows, research and analysis. Most recently, two online projects were announced; one on sustainability, which is becoming increasingly crucial for the mining sector and has already gone live. The other is a platform for raising capital, scheduled to launch in the second quarter of 2022.

    On November 3, the Company presented its fourth-quarter figures. The fiscal year ended September 30, 2021, and the transformation is bearing more and more fruit, which can be seen well in the quarterly figures. The first quarter was still weaker than in 2020, but since then, there has been growth. 2% in the second quarter, 11% in the third, and the fourth quarter increased by 24%. Revenue was AUD 4.3 million, and profit was AUD 2.8 million, an increase of 39%. The margin was a substantial 65% and also increased by 12% YOY. The Company was also able to announce that a live trade show is planned for the second quarter.

    Growth rates are now above pre-pandemic levels. Subscription numbers again grew by over 20%. All other lines of business also grew. Chief executive Alex Kent said in the wake of the figures, "..., and with the resumption of live events next March, we expect growth to be above average in the next fiscal year." The stock has not reacted at all to the positive news. Since October 18, the share has traded between AUD 0.02 and AUD 0.022. Chart-wise, the share becomes interesting with the break of the downtrend line. If a closing price above AUD 0.0222 succeeds, the trend line would be broken, initiating a breakout.

    TUI - Corona brings new worry lines

    TUI has suffered immensely from the Corona pandemic. While it looked for a short time as if the business outlook would improve, dark clouds are now gathering again. The Foreign Office advises against all cruises and journeys with Mein Schiff had to be canceled. The incidences in Austria are now exploding, which could again cause cancellations in the upcoming winter season. Already last year, the winter season was almost a total failure for the Company.

    At the same time, things seemed to be slowly looking up due to the vaccinations and the second capital increase in October of this year. Major shareholder Mordashov fully subscribed to the capital increase and held about 33% of the shares. The USA has allowed travel from Europe again since November 8. It is questionable whether this will continue if the incidences continue to rise. Every flare-up of the pandemic causes problems in the tourism industry.

    The share has therefore fallen again for a few days. Chart-wise, there is currently a shoulder-head-shoulder formation. If the share does not fall below EUR 2.61 on a closing price basis, a test of the EUR 3.00 mark is likely. Analysts currently take a critical view of the stock. 14 of 21 analysts have the stock at Sell, and only two see TUI as a Buy. The Company can only hope that the incidences do not climb further. Better yet, they fall quickly, but it does not look like that will happen at the moment.

    All three companies are turnaround candidates. TeamViewer benefits from Corona, but its earnings are burdened due to wrong decisions. TUI is weakening due to the pandemic. The commodities sector is also affected by Corona, but it does not affect Aspermont as much. Aspermont's numbers are improving, and the turnaround seems to have succeeded, even if the share has not yet taken off.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author

    Related comments:

    Commented by André Will-Laudien on January 31st, 2023 | 14:50 CET

    E-mobility 2023: The Tesla hunters are coming! BYD, Lucid Motors, Tocvan Ventures. Will the Varta share now also fly?

    • Mining
    • Gold
    • Electromobility
    • Investments

    It Is hard to believe! The Tesla share is once again making a name for itself. Analysts went into the presentation of the annual figures with cautious expectations because there were many negative rumors surrounding Elon Musk's electronics company: Fewer sales? Cars on stockpile? Again, it came as no one had expected it. Elon Musk delivered and simultaneously mocked all the shorties who wanted to push his stock below USD 100 at the turn of the year. This gambit went badly wrong because Tesla was able to deliver even better figures than expected, and there was no stopping the share. With plus 70% in only 4 weeks, the Tesla share belongs to the shooting stars since the turn of the year - the short sellers must have lost their desire completely. But the variety of interesting shares is significant. Where are the opportunities for e-investors lurking?


    Commented by Nico Popp on January 31st, 2023 | 14:33 CET

    This new project changes everything: Deutsche Bank, Aspermont, Alibaba

    • Digitization
    • Innovations
    • Technology
    • Investments

    When processes go digital, great opportunities arise: automation and scaling can ensure growth and turn established business models into high-flyers. But which companies should investors actively support in their transformation? Where is there real potential for investors, and where are companies just spreading buzzwords? We highlight three stocks for you.


    Commented by André Will-Laudien on January 30th, 2023 | 09:13 CET

    Mega biotech rally 2023! Defence Therapeutics, Bayer, BioNTech, Morphosys - Where to put the money?

    • Biotechnology
    • Cancer
    • Covid19
    • Investments

    Who would have thought it? Since the beginning of the year, the stock markets have been jubilant despite difficult predictions about the economic trend in 2023. High inflation and rising interest rates are not a good breeding ground for the popular biotech stocks because they have to constantly refinance their research expenses. As the risk fee is readjusted as costs rise, investors demand higher premiums for providing money. However, some biotech stocks have taken off since the beginning of the year despite adverse conditions. What is their secret?